menu
    • menu
    [{"orgOrder":0,"company":"Delta-Fly Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Ubenimex","moa":"||immunostimulants","graph1":"Oncology","graph2":"Phase III","graph3":"Delta-Fly Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Delta-Fly Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Delta-Fly Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Delta-Fly Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Ubenimex","moa":"||immunostimulants","graph1":"Oncology","graph2":"Phase III","graph3":"Delta-Fly Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Delta-Fly Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Delta-Fly Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Delta-Fly Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Ubenimex","moa":"||immunostimulants","graph1":"Oncology","graph2":"Phase III","graph3":"Delta-Fly Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Delta-Fly Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Delta-Fly Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Huashan Hospital","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"Huashan Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Huashan Hospital \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Huashan Hospital \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Region Skane","sponsor":"Swedish Lung Cancer Study Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase III","graph3":"Region Skane","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Region Skane \/ Swedish Lung Cancer Study Group","highestDevelopmentStatusID":"10","companyTruncated":"Region Skane \/ Swedish Lung Cancer Study Group"},{"orgOrder":0,"company":"Merus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merus \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merus \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Afatinib","moa":"||Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Ecog-Acrin Cancer Research Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"Ecog-Acrin Cancer Research Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ecog-Acrin Cancer Research Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ecog-Acrin Cancer Research Group \/ Undisclosed"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Boehringer Ingelheim GmbH | Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Boehringer Ingelheim GmbH | Incyte Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Massachusetts General Hospital \/ Boehringer Ingelheim GmbH | Incyte Corporation"},{"orgOrder":0,"company":"Moffitt Cancer Center","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"Moffitt Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moffitt Cancer Center \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Moffitt Cancer Center \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Michael Hopp","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase IV","graph3":"Michael Hopp","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Michael Hopp \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"11","companyTruncated":"Michael Hopp \/ Boehringer Ingelheim GmbH"}]

    Find Clinical Drug Pipeline Developments & Deals for Afatinib

    Menu

    Afatinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Delta-Fly Pharma

                            Japan arrow
                            FNCE
                            Not Confirmed

                            Delta-Fly Pharma

                            Japan arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ubenimex,Afatinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Delta-Fly Pharma Inc. Progress Update of the Phase III Clinical Trial of DFP-14323

                            Details : DFP-14323 (Ubenimex) is a small molecule CD13 inhibitor, currently being investigated in combination with Afatinib for patients with EGFR-mutated Non-Small-Cell Lung Cancer.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            November 26, 2024

                            Lead Product(s) : Ubenimex,Afatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Delta-Fly Pharma

                            Japan arrow
                            FNCE
                            Not Confirmed

                            Delta-Fly Pharma

                            Japan arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ubenimex,Afatinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Delta-Fly Pharma Begins Phase III Trial of DFP-14323

                            Details : DFP-14323 (Ubenimex) is a small molecule CD13 inhibitor, currently being investigated in combination with Afatinib for patients with EGFR-mutated Non-Small-Cell Lung Cancer.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            July 03, 2024

                            Lead Product(s) : Ubenimex,Afatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Region Skane

                            Country arrow
                            FNCE
                            Not Confirmed

                            Region Skane

                            Country arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Afatinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Swedish Lung Cancer Study Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study

                            Details : Afatinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 03, 2024

                            Lead Product(s) : Afatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Swedish Lung Cancer Study Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Massachusetts General Hospital

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            Massachusetts General Hospital

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Afatinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Boehringer Ingelheim GmbH | Incyte Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pemigatinib + Afatinib in Advanced Refractory Solid Tumors

                            Details : Afatinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 12, 2024

                            Lead Product(s) : Afatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Boehringer Ingelheim GmbH | Incyte Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Delta-Fly Pharma

                            Japan arrow
                            FNCE
                            Not Confirmed

                            Delta-Fly Pharma

                            Japan arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ubenimex,Afatinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Delta-Fly Pharma Initiates Phase III Trial Of DFP-14323

                            Details : Delta-Fly (ubenimex) is an aminopeptidase N inhibitor under Phase 3 trials in combination with afatinib for treating stage III/IV non-small cell lung cancer patients with EGFR mutations.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            February 02, 2024

                            Lead Product(s) : Ubenimex,Afatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Merus

                            Netherlands arrow
                            FNCE
                            Not Confirmed

                            Merus

                            Netherlands arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Afatinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

                            Details : Afatinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 20, 2022

                            Lead Product(s) : Afatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Huashan Hospital

                            Country arrow
                            FNCE
                            Not Confirmed

                            Huashan Hospital

                            Country arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Afatinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate the Efficacy of Afatinib in Skull Base Chordoma

                            Details : Afatinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Chordoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 29, 2022

                            Lead Product(s) : Afatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Boehringer Ingelheim GmbH

                            Germany arrow
                            FNCE
                            Not Confirmed

                            Boehringer Ingelheim GmbH

                            Germany arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Afatinib

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Afatinib (GILOTRIF®) in Patients Suffering From Tumors Harboring Neuregulin 1 (NRG1) Gene Alterations (Spec...

                            Details : Afatinib is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 04, 2021

                            Lead Product(s) : Afatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Moffitt Cancer Center

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            Moffitt Cancer Center

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Afatinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma

                            Details : Afatinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Squamous Cell.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 07, 2021

                            Lead Product(s) : Afatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Ecog-Acrin Cancer Research Group

                            Country arrow
                            FNCE
                            Not Confirmed

                            Ecog-Acrin Cancer Research Group

                            Country arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Afatinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Genomic Study of 6000 NCI-MATCH Cancer Patients Leads to New Clinical Trial Benchmarks

                            Details : The NCI-MATCH, a precision medicine study launched by the ECOG-ACRIN Cancer Research Group and the National Cancer Institute, has found that many patients’ tumors bear genetic abnormalities that can be targeted with existing drugs—approved or experim...

                            Product Name : Gilotrif

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 14, 2020

                            Lead Product(s) : Afatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth